哮喘-慢性阻塞性肺疾病患者临床治疗用药现状及其吸入给药装置的研究进展  

Research Progress of Clinical Medication Status and Inhalation Drug Delivery Device in Patients with Asthma and COPD

作　　者：梁文[1] 薛涛[1] 沈明云[1] 

机构地区：[1]扬子江药业集团有限公司,江苏泰州225321

出　　处：《抗感染药学》2016年第5期969-973,共5页Anti-infection Pharmacy

摘　　要：大气中污染空气的直径小于或等于2.5μm的颗粒物（PM 2.5）被称为可入肺颗粒物,大气污染已经危及到人们的身体健康和生命安全。由此引发的呼吸系统疾病正在吞噬越来越多的人的生命。目前,全球哮喘患者约3亿人,40岁以上慢性阻塞性肺部疾病（COPD）患者的患病率达8.2%。全球哮喘（Asthma）-COPD的治疗用药市场的消费额在40亿~480亿美金。综述哮喘-COPD患者临床治疗用药现状及其吸入给药装置的文献资料,并对其研究进展作了分析。The particulate matters in the atmospheric air pollution whose diameter is less than or equal to 2.5 μm （PM 2.5） can be inhaled by lungs. Air pollution has endangered people＇s health and safety. Respiratory disease caused by air pollution is threating more and more people＇s lives. Currently, about 300 million people are suffering from asthma and the prevalence rate of chronic obstructive pul- monary disease of over 46 years is 8.2%. The estimated sales of Asthma/COPD treatment drug in glob- al are 44 billion -48 billion dollars. The literatures on the research progress in clinical medication sta- tus and inhalation drug delivery device in patients with asthma and COPD have been reviewed, and their research progress has been analyzed.

关 键 词：哮喘 慢性阻塞性肺部疾病 给药装置 

分 类 号：R696[医药卫生—泌尿科学]